Reported 3 days ago
Wells Fargo has raised its price target for Kyverna Therapeutics (KYTX) to $27 from $24, maintaining an Overweight rating, as it expresses confidence in the upcoming trial readout for KYV-101 aimed at treating stiff person syndrome. The firm believes the trial is de-risked and highlights recent positive data from Phase 1 trials for KYV-101 in progressive multiple sclerosis, noting its favorable safety profile. Kyverna focuses on developing cell therapies for autoimmune diseases.
Source: YAHOO